Document is current
Any future updates will be listed below
-
Authors
Barabino, Stefano
Aragona, Pasquale
Baudouin, Christophe
Boboridis, Kostas
Salgado-Borges, José
Benitez-del-Castillo, Jose M.
Messmer, Elisabeth M.
Stanila, Adriana
Horwath-Winter, Jutta
Wylegala, Edward
Rolando, Maurizio
-
Funding
Funding for this research was provided by:
Alfa Intes
- License Information
-
More Information
Article History
Received: 27 December 2024
Accepted: 24 February 2025
First Online: 29 March 2025
Declarations
:
: Pasquale Aragona: Consultant for AbbVie, Alcon, Alfa Intes, Bausch and Lomb, DMG, FB Vision, Fidia, Santen, SIFI, Thea, TRB-Chemedica. Stefano Barabino: consultant for Fidia, TRB-Chemedica, Alfa Intes, Alcon. Christophe Baudouin: consultant for Alcon, Glaukos, Horus Pharma, Oculis, Santen, Thea. Elisabeth M. Messmer: speaker for: Alcon/Novartis, Bausch & Lomb, Dompé, Novartis, Santen GmbH, Théa Pharma GmbH, TRB-Chemedica AG, Visufarma. Consultant for: Alcon/Novartis, Alfa Intes, DMG, Dompé, Kala, Novartis, Santen GmbH, Shire, Sun, Sifi, Théa Pharma GmbH, TRB-Chemedica AG, Visufarma. José M. Benítez-del-Castillo: consultant for Brill, GSK, Santen, Sifi, Thea, Viatris. Jutta Horwath-Winter: Speaker or consultant for: Alfa Intes, Bausch & Lomb, Icom Medical, Laboratoires Thea, Mc2 Therapeutics, Santen, Shire, TRB-Chemedica, Ursapharm. Edward Wylegala: speaker for Alcon, Baush & Lomb, Thea Santen; consultant for: Optopol Technology. Kostas Boboridis, José Salgado-Borges, Adriana Stanila and Maurizio Rolando have nothing to disclose.
: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.
